CR8266A - Derivados de pirimidina para el tratamiento del crecimiento celular anormal - Google Patents

Derivados de pirimidina para el tratamiento del crecimiento celular anormal

Info

Publication number
CR8266A
CR8266A CR8266A CR8266A CR8266A CR 8266 A CR8266 A CR 8266A CR 8266 A CR8266 A CR 8266A CR 8266 A CR8266 A CR 8266A CR 8266 A CR8266 A CR 8266A
Authority
CR
Costa Rica
Prior art keywords
treatment
cellular growth
abnormal cellular
pirimidine derivatives
derivatives
Prior art date
Application number
CR8266A
Other languages
English (en)
Inventor
Charles Kath John
Joseph Luzzio Michael
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR8266A publication Critical patent/CR8266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a un compuesto de la formula I en la que R2- R4 son como se han definido en esta memoria. Tales nuevos derivados de pirimidina son utiles en el tratamiento del crecimiento celular anormal, tal como el cancer, en los mamiferos. esta invencion se refiere tambien a un metodo de uso de tales compuestos en el tratamiento del crecimiento celular anormal en los mamiferos especialmente en los seres humanos, y a composiciones farmaceuticas que contienen tales compuestos.
CR8266A 2002-12-20 2006-03-02 Derivados de pirimidina para el tratamiento del crecimiento celular anormal CR8266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43567002P 2002-12-20 2002-12-20
US50074203P 2003-09-05 2003-09-05

Publications (1)

Publication Number Publication Date
CR8266A true CR8266A (es) 2007-01-18

Family

ID=32685406

Family Applications (2)

Application Number Title Priority Date Filing Date
CR8266A CR8266A (es) 2002-12-20 2006-03-02 Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CR20110380A CR20110380A (es) 2002-12-20 2011-07-06 Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20110380A CR20110380A (es) 2002-12-20 2011-07-06 Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)

Country Status (31)

Country Link
US (4) US7109335B2 (es)
EP (1) EP1625121B1 (es)
AP (1) AP2385A (es)
AR (1) AR043682A1 (es)
AT (1) ATE458731T1 (es)
AU (2) AU2003285614B2 (es)
CA (1) CA2529611C (es)
CR (2) CR8266A (es)
CY (1) CY1110069T1 (es)
DE (1) DE60331479D1 (es)
DK (1) DK1625121T3 (es)
DO (1) DOP2003000793A (es)
EA (1) EA013248B1 (es)
EC (1) ECSP066406A (es)
ES (1) ES2338545T3 (es)
GE (1) GEP20084357B (es)
IL (1) IL172047A (es)
MX (1) MXPA06002608A (es)
MY (1) MY142109A (es)
NL (1) NL1025067C2 (es)
NZ (1) NZ543719A (es)
OA (1) OA13309A (es)
PA (1) PA8593001A1 (es)
PE (1) PE20041016A1 (es)
PL (1) PL379330A1 (es)
PT (1) PT1625121E (es)
RS (1) RS20060097A (es)
SI (1) SI1625121T1 (es)
TN (1) TNSN06074A1 (es)
TW (1) TWI283673B (es)
WO (1) WO2004056807A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA13309A (en) 2002-12-20 2007-04-13 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
MXPA06011890A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para tratar el crecimiento celular anomalo.
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
JP2007537235A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療用ピリミジン誘導体
WO2005111022A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005118544A2 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
BRPI0512342A (pt) * 2004-06-21 2008-03-04 Pharmacia & Upjohn Co Llc métodos para aumento ósseo
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
KR20080063846A (ko) * 2005-10-28 2008-07-07 아스트라제네카 아베 암 치료에서 티로신 키나제 억제제로 사용하기 위한4-(3-아미노피라졸)피리미딘 유도체
CA2632149C (en) * 2005-12-01 2011-11-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2673125C (en) * 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CA2681038A1 (en) * 2007-03-16 2008-09-25 University Of Florida Research Foundation Kinase protein binding inhibitors
EA016679B1 (ru) * 2007-04-18 2012-06-29 Пфайзер Продактс Инк. Сульфониламидные производные для лечения аномального роста клеток
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
CL2009000600A1 (es) * 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
RU2013147417A (ru) 2011-03-24 2015-04-27 Кемилиа Аб Новые производные пиримидина
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
EP2785709B1 (en) * 2011-11-29 2017-05-10 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
RU2014130214A (ru) 2011-12-23 2016-02-10 Целльзом Лимитид Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
TW202304434A (zh) * 2021-04-08 2023-02-01 大陸商杭州阿諾生物醫藥科技有限公司 一種高活性的ｈｐｋ１激酶抑制劑

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
DE4131184A1 (de) 1991-09-19 1993-03-25 Bayer Ag Wasserbasierte, loesungsmittel- und emulgatorfreie mikrobizide wirkstoffkombination
AU2954992A (en) 1991-11-13 1993-06-15 Mta Kozponti Kemiai Kutato Intezete Process for preparing n-(arylsulphonyl)-carbamide acid derivates and intermediates useful for carrying out this process
DE4137291A1 (de) 1991-11-13 1993-05-19 Bayer Ag Verfahren zur kontinuierlichen umsetzung von halogenpyrimidinen mit aminen
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2149815T3 (es) 1992-05-22 2000-11-16 Du Pont Imidazolinonas fungicidas.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
CA2233003A1 (en) 1995-10-02 1997-04-10 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c-receptor antagonists
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
AU3766897A (en) 1996-07-13 1998-02-09 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
BR9710362A (pt) 1996-07-13 1999-08-17 Glaxo Group Ltd Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
EP0920429B1 (en) 1996-08-06 2003-02-19 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
CN1234031A (zh) 1996-09-04 1999-11-03 辉瑞大药厂 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
DE19701931C1 (de) 1997-01-21 1998-05-28 Siemens Ag Verfahren zur Detektion von Synchronizität zwischen mehreren digitalen Meßreihen mit Hilfe eines Rechners
ATE345339T1 (de) 1997-02-19 2006-12-15 Berlex Lab N-heterocyclische derivate als nos inhibitoren
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
JP2002503662A (ja) 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
AU6159499A (en) 1998-09-29 2000-04-17 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CA2402742C (en) 2000-03-13 2009-05-12 American Cyanamid Company Method of treating or inhibiting colonic polyps
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
AU2001269291A1 (en) 2000-07-07 2002-02-05 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
IL154034A0 (en) 2000-08-09 2003-07-31 Astrazeneca Ab Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals
US6887874B2 (en) 2000-08-09 2005-05-03 Astrazeneca Ab Cinnoline compounds
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
EP1313727A1 (en) 2000-08-21 2003-05-28 AstraZeneca AB Quinazoline derivatives
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
DE60138645D1 (de) 2000-12-21 2009-06-18 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
EP1392662B1 (de) 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2475141A1 (en) 2002-02-05 2003-08-14 Wyeth Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
DE10205336A1 (de) 2002-02-07 2003-08-21 Bdd Group Holding Ag Zug Deuterierte Biphenylderivate
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
NZ539488A (en) 2002-12-20 2008-03-28 Arakis Ltd Benzoxazocines and their use as monoamine-reuptake inhibitors
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
OA13309A (en) * 2002-12-20 2007-04-13 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0414059B8 (pt) 2003-09-05 2021-05-25 Pfizer Prod Inc síntese seletiva de pirimidinas substituídas em cf3
JP2007537235A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療用ピリミジン誘導体
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
EA200600122A1 (ru) 2006-06-30
PA8593001A1 (es) 2005-02-04
RS20060097A (en) 2008-11-28
US7741336B2 (en) 2010-06-22
PT1625121E (pt) 2010-03-11
US20060281774A1 (en) 2006-12-14
WO2004056807A1 (en) 2004-07-08
MY142109A (en) 2010-09-15
NZ543719A (en) 2007-01-26
IL172047A (en) 2012-04-30
DE60331479D1 (de) 2010-04-08
TWI283673B (en) 2007-07-11
IL172047A0 (en) 2009-02-11
US20050009853A1 (en) 2005-01-13
CA2529611A1 (en) 2004-07-08
DK1625121T3 (da) 2010-05-10
DOP2003000793A (es) 2011-07-31
EP1625121A1 (en) 2006-02-15
CA2529611C (en) 2009-12-15
EP1625121B1 (en) 2010-02-24
US20080182840A1 (en) 2008-07-31
US7351712B2 (en) 2008-04-01
AP2005003438A0 (en) 2005-12-31
AR043682A1 (es) 2005-08-10
ECSP066406A (es) 2006-09-18
SI1625121T1 (sl) 2010-04-30
US7109335B2 (en) 2006-09-19
AU2003285614A1 (en) 2004-07-14
ATE458731T1 (de) 2010-03-15
AU2003285614B2 (en) 2009-05-14
US7674796B2 (en) 2010-03-09
GEP20084357B (en) 2008-04-29
CR20110380A (es) 2011-08-08
TNSN06074A1 (en) 2007-10-03
US20080300234A1 (en) 2008-12-04
OA13309A (en) 2007-04-13
PL379330A1 (pl) 2006-08-21
NL1025067A1 (nl) 2004-06-22
CY1110069T1 (el) 2015-01-14
MXPA06002608A (es) 2007-01-23
ES2338545T3 (es) 2010-05-10
NL1025067C2 (nl) 2005-02-15
TW200426148A (en) 2004-12-01
EA013248B1 (ru) 2010-04-30
AU2009208172B2 (en) 2011-06-16
AP2385A (en) 2012-03-23
PE20041016A1 (es) 2004-12-30
AU2009208172A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
CR8266A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8777101A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
HN2003000422A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
ECSP088563A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CR8749A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
PA8561301A1 (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal
ECSP055633A (es) Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos
UY28150A1 (es) Agentes terapeuticos
UY28514A1 (es) Nuevos compuestos
UY29149A1 (es) Tiazolil-dihidro-indazoles
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY29613A1 (es) Compuestos quimicos vi
UY28695A1 (es) Derivados de difenilazetidona
PA8587501A1 (es) Benzoxazinonas sustituidas y usos de las mismas
SV2006002089A (es) Nuevos imidazoles ref. docket 18699 (pc26195a)
PA8589801A1 (es) Aminoalcoxiindoles
PA8571401A1 (es) Imidazolinilmetil aralquilsulfonamidas
PA8568901A1 (es) Nuevos derivados de azepano
UY28136A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
NI200500205A (es) "derivados de pirimidina para el tratamiento del crecimiento celular anorma."
DOP2005000086A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
UY28104A1 (es) Aminoalcoxiindoles
DOP2003000715A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa